Tenon Medical, Inc. plans to list on the Nasdaq Capital Market under the symbol TNON. It filed a Form S-1 registration statement for an initial public offering on August 14, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, June 30, 2026).
Sell to companies like Tenon Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Tenon Medical, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-14. It has amended it 4 times. It filed its final prospectus on 2026-06-30. Each fact below is quoted from the filing named with it.
Also on the record for Tenon Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 21, 2026 | Form D, private offering | $4.31M sold | Form D page | Source |
| September 4, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| July 6, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| March 18, 2026 | Form D, private offering | $4.30M sold | Form D page | Source |
| November 25, 2025 | Form D, private offering | $2.85M sold | Form D page | Source |
| August 8, 2025 | Stake report, Schedule 13D, by SiVantage Inc. | 12.5% of the class | 5%+ stakes | Source |
| April 8, 2025 | Form D, private offering | $2.54M sold | Form D page | Source |
| April 8, 2025 | Form D, private offering | $1.47M sold | Form D page | Source |
| April 8, 2025 | Form D, private offering | $4.59M sold | Form D page | Source |
Check before you invest in Tenon Medical, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Tenon Medical, Inc. and the records around it.
Tenon Medical, Inc. elsewhere on the record
- Company profile and every filing Sep 2026
- Form D filing Sep 2026
- Form D filing Sep 2026
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q2 2026, newest first.
- Exyn Technologies, Inc. (Jun 2026)
- bioAffinity Technologies, Inc. (Jun 2026)
Watch Tenon Medical, Inc.
Get an email when Tenon Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tenon Medical, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tenon Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tenon Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “TNON.” The last reported sale price of our common stock on The Nasdaq Capital Market on June 29, 2026 was $0.4465 per share.From the 424B4 filed 2026-06-30
Shares offered
We are offering on a reasonable best efforts basis up to 5,526,315 shares of our common stock, par value $0.001 per share, together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the “Common Warrants”), at a combined public offering price of $0.38 per share of common stock and accompanying Common Warrants; provided however, if we effect a reverse stock split, the number of shares of common stock issuable under the Common Warrants will increase to 16,578,947 (on a pre-stock split basis).From the 424B4 filed 2026-06-30
Use of proceeds
We currently intend to use the net proceeds to us from this offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of our product portfolio including training clinicians on our current procedures, hiring additional direct sales reps, expansion of our external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.From the 424B4 filed 2026-06-30
Net loss or income
The decrease in net cash used in operating activities for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023 was primarily attributable to our decreased net loss of $1.7 million, adjusted for decreases in non-cash stock-based compensation expenses ($42), in addition to increased accounts payable ($316), partially offset by decreases in accrued expenses ($313).From the S-1/A filed 2024-11-04
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-14 | Registration statement filed | S-1 |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2024-09-16 | Final prospectus filed: the offering is priced | 424B4 |
| 2024-10-17 | Registration statement filed | S-1 |
| 2024-11-04 | Registration statement amended | S-1/A |
| 2025-04-04 | Registration statement filed | S-1 |
| 2026-06-22 | Registration statement filed | S-1 |
| 2026-06-26 | Registration statement amended | S-1/A |
| 2026-06-30 | Final prospectus filed: the offering is priced | 424B4 |
Tenon Medical, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Tenon Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.